Dietary supplements in patients with cancer: risks and key concepts, part 1.
OBJECTIVE
The risks and key concepts regarding the use of dietary supplements in patients with cancer are described.


CONCLUSIONS
There are six common characteristics of dietary supplements that must be addressed when used by patients with cancer. Clinicians must establish if the supplement is an antioxidant, is an anticoagulant or procoagulant, has immunosuppressive or immunomodulating properties, has hormonal properties, has known safety issues, and has known or theoretical drug interactions. These six characteristics of the dietary supplements commonly used by patients with cancer are reviewed to aid in the analysis of the scientific data and communication of the results with the patient or family members. A framework upon which clinicians can adequately help patients make informed decisions regarding the use of complimentary and alternative medicine and dietary supplements is also described. When evaluating the appropriateness of a supplement for use by a patient with cancer, clinicians must conduct a safety review (evaluate the six characteristics). If the supplement is considered safe, an efficacy review must be conducted, after which the clinicians can recommend the supplement's use, accept the patient's decision to use the supplement if no or inconclusive evidence exists, or discourage use if there is conclusive evidence supporting inefficacy. Available resources for locating information regarding dietary supplements are also discussed.


CONCLUSIONS
Counseling patients with cancer about dietary supplements requires a systematic thought process that considers the available theories and data, as well as the patients' views about the agents.
Michaud
Laura Boehnke
LB
Division of Pharmacy, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA. lboehnke@mdanderson.org
Karpinski
Julie Phillips
JP
Jones
Kellie L
KL
Espirito
Janet
J
D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D000529:Complementary Therapies; D019587:Dietary Supplements / Q000009:adverse effects; D004347:Drug Interactions; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D010353:Patient Education as Topic
D000970:Antineoplastic Agents